# Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population

> **NCT02661490** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 320 (actual)

## Conditions studied

- Norovirus

## Interventions

- **BIOLOGICAL:** Norovirus GI.1/GII.4 Bivalent VLP Vaccine
- **DRUG:** 0.9% sodium chloride (saline)
- **BIOLOGICAL:** Norovirus GI.1/GII.4 Bivalent VLP Vaccine

## Key facts

- **NCT ID:** NCT02661490
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-01
- **Primary completion:** 2016-10-28
- **Final completion:** 2017-09-29
- **Target enrollment:** 320 (ACTUAL)
- **Last updated:** 2020-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02661490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02661490, "Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02661490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*